AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that previously reported positive clinical data evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC) will be featured in several poster presentations at the American Society of Clinical Oncology (ASCO) 2011 Genitourinary Cancers Symposium being held February 17-19, 2011 at the Orlando World Center Marriott in Orlando, Fla.
William Slichenmyer, M.D., Sc.M., chief medical officer at AVEO, said, "We are delighted with the interest tivozanib is receiving from the oncology community as a potential new treatment option for patients with RCC and other forms of cancer. We are eagerly awaiting the top-line data from our Phase 3 TIVO-1 trial in mid-2011, and based on the results of our Phase 2 clinical trial, we believe that tivozanib may be an important new therapy for patients with RCC."
The tivozanib posters will be presented during General Poster Session D: Renal Cancer on Saturday, February 19, 2011 from 7:00 a.m. to 8:00 a.m. and again from 11:05 a.m. to 1:05 p.m. (EST). Additional presentation details are as follows:
Following the symposium, the posters will be available in the publications section of the AVEO website at investor.aveopharma.com.
Study shows AI can predict prognosis in triple-negative breast cancer